# A Single Dose of Pembrolizumab in HIV-Infected People

> **NCT03367754** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 11 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **OTHER:** Placebo
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03367754
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-06
- **Primary completion:** 2021-12-17
- **Final completion:** 2024-11-18
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Difficulty with subject recruitment
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367754, "A Single Dose of Pembrolizumab in HIV-Infected People". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03367754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*